Effect of Levothyroxine Therapy on the Development of Depressive Symptoms in Older Adults With Subclinical Hypothyroidism: An Ancillary Study of a Randomized Clinical Trial | Depressive Disorders | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.177.17. Please contact the publisher to request reinstatement.
1.
Biondi  B, Cappola  AR, Cooper  DS.  Subclinical hypothyroidism: a review.   JAMA. 2019;322(2):153-160. doi:10.1001/jama.2019.9052PubMedGoogle ScholarCrossref
2.
Canaris  GJ, Manowitz  NR, Mayor  G, Ridgway  EC.  The Colorado thyroid disease prevalence study.   Arch Intern Med. 2000;160(4):526-534. doi:10.1001/archinte.160.4.526PubMedGoogle ScholarCrossref
3.
Cooper  DS, Biondi  B.  Subclinical thyroid disease.   Lancet. 2012;379(9821):1142-1154. doi:10.1016/S0140-6736(11)60276-6PubMedGoogle ScholarCrossref
4.
Biondi  B, Cooper  DS.  The clinical significance of subclinical thyroid dysfunction.   Endocr Rev. 2008;29(1):76-131. doi:10.1210/er.2006-0043PubMedGoogle ScholarCrossref
5.
Bekkering  GE, Agoritsas  T, Lytvyn  L,  et al.  Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline.   BMJ. 2019;365:l2006. doi:10.1136/bmj.l2006PubMedGoogle ScholarCrossref
6.
Stott  DJ, Rodondi  N, Kearney  PM,  et al; TRUST Study Group.  Thyroid hormone therapy for older adults with subclinical hypothyroidism.   N Engl J Med. 2017;376(26):2534-2544. doi:10.1056/NEJMoa1603825PubMedGoogle ScholarCrossref
7.
Feller  M, Snel  M, Moutzouri  E,  et al.  Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis.   JAMA. 2018;320(13):1349-1359. doi:10.1001/jama.2018.13770PubMedGoogle ScholarCrossref
8.
Jonklaas  J, Bianco  AC, Bauer  AJ,  et al; American Thyroid Association Task Force on Thyroid Hormone Replacement.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.   Thyroid. 2014;24(12):1670-1751. doi:10.1089/thy.2014.0028PubMedGoogle ScholarCrossref
9.
Pearce  SH, Brabant  G, Duntas  LH,  et al.  2013 ETA Guideline: management of subclinical hypothyroidism.   Eur Thyroid J. 2013;2(4):215-228. doi:10.1159/000356507PubMedGoogle ScholarCrossref
10.
Rodriguez-Gutierrez  R, Maraka  S, Ospina  NS, Montori  VM, Brito  JP.  Levothyroxine overuse: time for an about face?   Lancet Diabetes Endocrinol. 2017;5(4):246-248. doi:10.1016/S2213-8587(16)30276-5PubMedGoogle ScholarCrossref
11.
Leading chemical drugs dispenses in England in 2019. Published 2020. Accessed July 10, 2020. https://www.statista.com/statistics/378445/prescription-cost-analysis-top-twenty-chemicals-by-items-in-england/
12.
Allport  J, McCahon  D, Hobbs  FD, Roberts  LM.  Why are GPs treating subclinical hypothyroidism? case note review and GP survey.   Prim Health Care Res Dev. 2013;14(2):175-184. doi:10.1017/S1463423612000230PubMedGoogle ScholarCrossref
13.
Stott  DJ, Gussekloo  J, Kearney  PM,  et al.  Study protocol; thyroid hormone replacement for untreated older adults with subclinical hypothyroidism—a randomised placebo controlled trial (TRUST).   BMC Endocr Disord. 2017;17(1):6. doi:10.1186/s12902-017-0156-8PubMedGoogle ScholarCrossref
14.
The TRUST Study—Depression Substudy (TRUST). Clinicaltrials.gov identifier: NCT01853579. Updated June 14, 2018. Accessed January 4, 2021. https://clinicaltrials.gov/ct2/show/NCT01853579
15.
Schulz  KF, Altman  DG, Moher  D; CONSORT Group.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.   BMJ. 2010;340:c332. doi:10.1136/bmj.c332PubMedGoogle ScholarCrossref
16.
de Craen  AJ, Heeren  TJ, Gussekloo  J.  Accuracy of the 15-item geriatric depression scale (GDS-15) in a community sample of the oldest old.   Int J Geriatr Psychiatry. 2003;18(1):63-66. doi:10.1002/gps.773PubMedGoogle ScholarCrossref
17.
Sheikh  JI, Yesavage  JA, Brooks  JO  III,  et al.  Proposed factor structure of the Geriatric Depression Scale.   Int Psychogeriatr. 1991;3(1):23-28. doi:10.1017/S1041610291000480PubMedGoogle ScholarCrossref
18.
Vinkers  DJ, Gussekloo  J, Stek  ML, Westendorp  RG, Van Der Mast  RC.  The 15-item Geriatric Depression Scale (GDS-15) detects changes in depressive symptoms after a major negative life event: the Leiden 85-plus Study.   Int J Geriatr Psychiatry. 2004;19(1):80-84. doi:10.1002/gps.1043PubMedGoogle ScholarCrossref
19.
Sundermann  EE, Katz  MJ, Lipton  RB.  Sex differences in the relationship between depressive symptoms and risk of amnestic mild cognitive impairment.   Am J Geriatr Psychiatry. 2017;25(1):13-22. doi:10.1016/j.jagp.2016.08.022PubMedGoogle ScholarCrossref
20.
Chwastiak  L, Ehde  DM, Gibbons  LE, Sullivan  M, Bowen  JD, Kraft  GH.  Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.   Am J Psychiatry. 2002;159(11):1862-1868. doi:10.1176/appi.ajp.159.11.1862PubMedGoogle ScholarCrossref
21.
Vogelzangs  N, Beekman  AT, Boelhouwer  IG,  et al.  Metabolic depression: a chronic depressive subtype? Findings from the InCHIANTI study of older persons.   J Clin Psychiatry. 2011;72(5):598-604. doi:10.4088/JCP.10m06559PubMedGoogle ScholarCrossref
22.
Morsink  LF, Vogelzangs  N, Nicklas  BJ,  et al; Health ABC study.  Associations between sex steroid hormone levels and depressive symptoms in elderly men and women: results from the Health ABC study.   Psychoneuroendocrinology. 2007;32(8-10):874-883. doi:10.1016/j.psyneuen.2007.06.009PubMedGoogle ScholarCrossref
23.
Vilagut  G, Forero  CG, Barbaglia  G, Alonso  J.  Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES-D): a systematic review with meta-analysis.   PLoS One. 2016;11(5):e0155431. doi:10.1371/journal.pone.0155431PubMedGoogle Scholar
24.
Imai  H, Furukawa  TA, Kasahara  Y,  et al.  Ipsative imputation for a 15-item Geriatric Depression Scale in community-dwelling elderly people.   Psychogeriatrics. 2014;14(3):182-187. doi:10.1111/psyg.12060PubMedGoogle ScholarCrossref
25.
le Cessie  S, Goeman  JJ, Dekkers  OM.  Who is afraid of non-normal data? choosing between parametric and non-parametric tests.   Eur J Endocrinol. 2020;182(2):E1-E3. doi:10.1530/EJE-19-0922Google Scholar
26.
Altman  NS.  An introduction to kernel and nearest-neighbor nonparametric regression.   The American Statistician. 1992;46(3):175-185. doi:10.1080/00031305.1992.10475879Google Scholar
27.
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Updated March 2011. Accessed July 7, 2020. https://handbook-5-1.cochrane.org/
28.
Schünemann H, Brożek J, Guyatt G, Oxman  A, eds. GRADE Handbook. Updated October 2013. Accessed December 31, 2020. https://gdt.gradepro.org/app/handbook/handbook.html
29.
Jorde  R, Waterloo  K, Storhaug  H, Nyrnes  A, Sundsfjord  J, Jenssen  TG.  Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment.   J Clin Endocrinol Metab. 2006;91(1):145-153. doi:10.1210/jc.2005-1775PubMedGoogle ScholarCrossref
30.
Reuters  VS, Almeida  CdeP, Teixeira  PdeF,  et al.  Effects of subclinical hypothyroidism treatment on psychiatric symptoms, muscular complaints, and quality of life.   Arq Bras Endocrinol Metabol. 2012;56(2):128-136. doi:10.1590/S0004-27302012000200006PubMedGoogle ScholarCrossref
31.
Najafi  L, Malek  M, Hadian  A, Ebrahim Valojerdi  A, Khamseh  ME, Aghili  R.  Depressive symptoms in patients with subclinical hypothyroidism—the effect of treatment with levothyroxine: a double-blind randomized clinical trial.   Endocr Res. 2015;40(3):121-126. doi:10.3109/07435800.2014.896924PubMedGoogle ScholarCrossref
32.
Blum  MR, Wijsman  LW, Virgini  VS,  et al; PROSPER study group.  Subclinical thyroid dysfunction and depressive symptoms among the elderly: a prospective cohort study.   Neuroendocrinology. 2016;103(3-4):291-299. doi:10.1159/000437387PubMedGoogle ScholarCrossref
33.
Demartini  B, Ranieri  R, Masu  A, Selle  V, Scarone  S, Gambini  O.  Depressive symptoms and major depressive disorder in patients affected by subclinical hypothyroidism: a cross-sectional study.   J Nerv Ment Dis. 2014;202(8):603-607. doi:10.1097/NMD.0000000000000168PubMedGoogle ScholarCrossref
34.
Grabe  HJ, Völzke  H, Lüdemann  J,  et al.  Mental and physical complaints in thyroid disorders in the general population.   Acta Psychiatr Scand. 2005;112(4):286-293. doi:10.1111/j.1600-0447.2005.00586.xPubMedGoogle ScholarCrossref
35.
Gussekloo  J, van Exel  E, de Craen  AJ, Meinders  AE, Frölich  M, Westendorp  RG.  Thyroid status, disability and cognitive function, and survival in old age.   JAMA. 2004;292(21):2591-2599. doi:10.1001/jama.292.21.2591PubMedGoogle ScholarCrossref
36.
Hong  JW, Noh  JH, Kim  DJ.  Association between subclinical thyroid dysfunction and depressive symptoms in the Korean adult population: The 2014 Korea National Health and Nutrition Examination Survey.   PLoS One. 2018;13(8):e0202258. doi:10.1371/journal.pone.0202258PubMedGoogle Scholar
37.
Loh  HH, Lim  LL, Yee  A, Loh  HS.  Association between subclinical hypothyroidism and depression: an updated systematic review and meta-analysis.   BMC Psychiatry. 2019;19(1):12. doi:10.1186/s12888-018-2006-2PubMedGoogle ScholarCrossref
38.
Park  YJ, Lee  EJ, Lee  YJ,  et al.  Subclinical hypothyroidism (SCH) is not associated with metabolic derangement, cognitive impairment, depression or poor quality of life (QoL) in elderly subjects.   Arch Gerontol Geriatr. 2010;50(3):e68-e73. doi:10.1016/j.archger.2009.05.015PubMedGoogle ScholarCrossref
39.
Wildisen  L, Del Giovane  C, Moutzouri  E,  et al.  An individual participant data analysis of prospective cohort studies on the association between subclinical thyroid dysfunction and depressive symptoms.   Sci Rep. 2020;10(1):19111. doi:10.1038/s41598-020-75776-1PubMedGoogle ScholarCrossref
40.
Parle  J, Roberts  L, Wilson  S,  et al.  A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study.   J Clin Endocrinol Metab. 2010;95(8):3623-3632. doi:10.1210/jc.2009-2571PubMedGoogle ScholarCrossref
41.
Garber  JR, Cobin  RH, Gharib  H,  et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults.  Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.   Thyroid. 2012;22(12):1200-1235. doi:10.1089/thy.2012.0205PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Views 6,581
    Citations 0
    Original Investigation
    Diabetes and Endocrinology
    February 10, 2021

    Effect of Levothyroxine Therapy on the Development of Depressive Symptoms in Older Adults With Subclinical Hypothyroidism: An Ancillary Study of a Randomized Clinical Trial

    Author Affiliations
    • 1Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
    • 2Graduate School for Health Sciences, University of Bern, Bern, Switzerland
    • 3Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
    • 4Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands
    • 5Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands
    • 6Service of Endocrinology, Diabetology, Nutrition, and Therapeutic Education, Geneva University Hospitals, Geneva, Switzerland
    • 7School of Public Health, University College Cork, Cork, Ireland
    • 8Institute of Cardiovascular Medicine, University of Glasgow, Glasgow, Scotland
    • 9University Hospital of Old Age Psychiatry, University of Bern, Bern, Switzerland
    • 10Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California
    • 11Department of Medicine, Erasmus Medical Center, Rotterdam, the Netherland
    • 12Department of Public Health and Center for Healthy Aging, University of Copenhagen, Copenhagen, Denmark
    JAMA Netw Open. 2021;4(2):e2036645. doi:10.1001/jamanetworkopen.2020.36645
    Key Points

    Question  Does levothyroxine treatment have an effect on the development of depressive symptoms in older adults with subclinical hypothyroidism?

    Findings  In this ancillary study of a randomized, placebo-controlled clinical trial of 427 participants with subclinical hypothyroidism, there was no statistically significant difference in the adjusted between-group difference in the mean Geriatric Depression Score at 12 months between the levothyroxine and placebo groups.

    Meaning  These results do not provide evidence in favor of levothyroxine therapy in older persons with subclinical hypothyroidism to reduce the risk of developing depressive symptoms.

    Abstract

    Importance  Previous trials on the effect of levothyroxine on depressive symptom scores in patients with subclinical hypothyroidism were limited by small sample sizes (N = 57 to 94) and potential biases.

    Objective  To assess the effect of levothyroxine on the development of depressive symptoms in older adults with subclinical hypothyroidism in the largest trial on this subject and to update a previous meta-analysis including the results from this study.

    Design, Setting, and Participants  This predefined ancillary study analyzed data from participants in the Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism (TRUST) trial, a double-blind, randomized, placebo-controlled, parallel-group clinical trial conducted from April 2013 to October 31, 2016. The TRUST trial included adults aged 65 years or older diagnosed with subclinical hypothyroidism, defined as the presence of persistently elevated thyroid-stimulating hormone (TSH) levels (4.6-19.9 mIU/L) with free thyroxine (T4) within the reference range. Participants were identified from clinical and general practitioner laboratory databases and recruited from the community in Switzerland, the Netherlands, Ireland, and the UK. This ancillary study included a subgroup of 472 participants from the Netherlands and Switzerland; after exclusions, a total of 427 participants (211 randomized to levothyroxine and 216 to placebo) were analyzed. This analysis was conducted from December 1, 2019, to September 1, 2020.

    Interventions  Randomization to either levothyroxine or placebo.

    Main Outcomes and Measures  Depressive symptom scores after 12 months measured with the Geriatric Depression Scale (GDS-15), with higher scores indicating more depressive symptoms (minimal clinically important difference = 2).

    Results  A total of 427 participants with subclinical hypothyroidism (mean [SD] age, 74.52 [6.29] years; 239 women [56%]) were included in this analysis. The mean (SD) TSH level was 6.57 (2.22) mIU/L at baseline and decreased after 12 months to 3.83 (2.29) mIU/L in the levothyroxine group; in the placebo group, it decreased from 6.55 (2.04) mIU/L to 5.91 (2.66) mIU/L. At baseline, the mean (SD) GDS-15 score was 1.26 (1.85) in the levothyroxine group and 0.96 (1.58) in the placebo group. The mean (SD) GDS-15 score at 12 months was 1.39 (2.13) in the levothyroxine and 1.07 (1.67) in the placebo group with an adjusted between-group difference of 0.15 for levothyroxine vs placebo (95% CI, −0.15 to 0.46; P = .33). In a subgroup analysis including participants with a GDS-15 of at least 2, the adjusted between-group difference was 0.61 (95% CI, −0.32 to 1.53; P = .20). Results did not differ according to age, sex, or TSH levels. A previous meta-analysis (N = 278) on the association of levothyroxine with depressive symptoms was updated to include these findings, resulting in an overall standardized mean difference of 0.09 (95% CI, −0.05 to 0.22).

    Conclusions and Relevance  This ancillary study of a randomized clinical trial found that depressive symptoms did not differ after levothyroxine therapy compared with placebo after 12 months; thus, these results do not provide evidence in favor of levothyroxine therapy in older persons with subclinical hypothyroidism to reduce the risk of developing depressive symptoms.

    Trial Registration  ClinicalTrials.gov Identifier: NCT01853579

    ×